Development of new strategy for end stage dilated cardiomyopathy, a combination of left ventricular assist device and aoutologous myoblast sheets

Development of new strategy for end stage dilated cardiomyopathy, a combination of left ventricular assist device and aoutologous myoblast sheets - A combination of left ventricular assist device and aoutologous myoblast sheets for end stage dilated cardiomyopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000660

Enrollment

Registered

2007-04-01

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage dilated cardiomyopathy patients who need LVAS

Interventions

Culture of autologous skeltal myoblasts and engineering myoblast sheets. Transplantation of the myoblast sheets to the heart in the combination with LVAS implantation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: End stage dilated cardiomyopathy Requiring LVAS

Exclusion criteria

Exclusion criteria: Severe skeletal muscle disease Cancer Severe infection Alcoholic or drug addiction in recent six months Pregnancy Others (doctors dicision)

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
Caridac function	—

Countries

Japan

Contacts

Public ContactGoro Matsumiya

Osaka University Graduate school of medicine Cardiovascular surgery

matsumg@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026